All patients in our study underwent TSC1/2 gene test, four patients had mutations in pathogenic TSC1 or TSC2 genes, five patients met the clinical or genetic diagnostic criteria for tuberous sclerosis, accounting for 35.7% (5/14) of EAML patients diagnosed in our hospital during the same period. This evidence concerns the gene TSC1 and tuberous sclerosis.